All trans retinoic acid as a host-directed immunotherapy for tuberculosis
Tuberculosis (TB) is the top bacterial infectious disease killer and one of the top ten causes of death worldwide. The emergence of strains of multiple drug-resistant tuberculosis (MDR-TB) has pushed our available stock of anti-TB agents to the limit of effectiveness. This has increased the urgent n...
Main Authors: | Ahmad Z. Bahlool, Conor Grant, Sally-Ann Cryan, Joseph Keane, Mary P. O'Sullivan |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-01-01
|
Series: | Current Research in Immunology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S259025552200004X |
Similar Items
-
Development of Inhalable ATRA-Loaded PLGA Nanoparticles as Host-Directed Immunotherapy against Tuberculosis
by: Ahmad Z. Bahlool, et al.
Published: (2022-08-01) -
Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis
by: Ralf Boland, et al.
Published: (2023-02-01) -
Cellular therapy in Tuberculosis
by: Shreemanta K. Parida, et al.
Published: (2015-03-01) -
All-trans retinoic acid (ATRA) reduces proliferative capacity and Brachyury levels in the chordoma cell line UCH-1
by: Helena Robinson, et al.
Published: (2020-01-01) -
Co-delivery of Dacarbazine and All-Trans Retinoic Acid (ATRA) Using Lipid Nanoformulations for Synergistic Antitumor Efficacy Against Malignant Melanoma
by: Chenyang Li, et al.
Published: (2020-05-01)